NCT01753739View on ClinicalTrials.gov

Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)

PHASE2CompletedINTERVENTIONAL
Enrollment

617

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 28, 2013

Study Completion Date

May 31, 2013

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

Bepotastine besilate

Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days

DRUG

Placebo

Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days

Trial Locations (1)

92618-2301

Bausch & Lomb Incorporated, Irvine

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01753739 - Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR) | Biotech Hunter | Biotech Hunter